Survodutide

Also known as: Survodutide

An investigational GLP-1/glucagon dual agonist studied for obesity and liver disease.

⚕️ Educational reference only — not medical advice. Many peptides are not approved for human use and are sold for research purposes only. Always consult a qualified healthcare professional.

Overview

Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, in clinical development for weight management and metabolic liver disease (MASH).

How It's Thought to Work

Combining GLP-1 and glucagon-receptor activity is being studied to affect appetite, energy expenditure, and liver fat.

What the Research Says

Supported by ongoing human clinical trials; not yet approved.

Regulatory & Legal Status

Investigational — not FDA-approved. Consumer 'research chemical' versions are unapproved and unregulated.

Safety Considerations

Long-term human safety is still being established in trials. Consult a clinician.

Frequently Asked Questions

What is Survodutide?

Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, in clinical development for weight management and metabolic liver disease (MASH).

How does Survodutide work?

Combining GLP-1 and glucagon-receptor activity is being studied to affect appetite, energy expenditure, and liver fat.

What does the research say about Survodutide?

Supported by ongoing human clinical trials; not yet approved.

Is Survodutide FDA-approved or legal to buy?

Investigational — not FDA-approved. Consumer 'research chemical' versions are unapproved and unregulated.

Is Survodutide safe? What are the risks?

Long-term human safety is still being established in trials. Consult a clinician.

Want the latest on Survodutide as it publishes?

Browse Research All Peptide Guides